This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
Bringing their expertise, we are thrilled to introduce Dr Matthew Nelson, Vice President, Genetics and Genomics, Deerfield Discovery and Development and CEO at Genscience and Dr Jake Rubens, President of Quotient Therapeutics and Origination Partner at Flagship Pioneering.
Key discussion points:
DNA has been called the code of life. How much of this code have we deciphered?
How is technology evolving to allow us to better understand the consequences of genetic changes (DNA mutations, epigenetics, etc.) and health and disease? What impact do we expect this to have in drug discovery?
How do we go from sequencing the DNA of individuals to making connections to health and disease? What are some examples of gene-disease links we’ve made that have informed drug target selection?
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
